Journal of Oral Medicine and Pain

Korean Academy of Orofacial Pain and Oral Medicine (대한안면통증구강내과학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical Features Affecting the Efficacy of Systemic Clonazepam for Management of Burning Mouth Syndrome

구강작열감증후군의 치료를 위한 전신적 클로나제팜의 투여 시 환자의 임상적 특징에 따른 효능의 차이에 관한 연구

  • Min, Bo-Kyong (Department of Oral Medicine, School of Dentistry, Kyungpook National University) ;
  • Jung, Jae-Kwang (Department of Oral Medicine, School of Dentistry, Kyungpook National University) ;
  • Choi, Jae-Kap (Department of Oral Medicine, School of Dentistry, Kyungpook National University)
  • 민보경 (경북대학교 치의학전문대학원 구강내과학 교실) ;
  • 정재광 (경북대학교 치의학전문대학원 구강내과학 교실) ;
  • 최재갑 (경북대학교 치의학전문대학원 구강내과학 교실)
  • Received : 2012.07.25
  • Accepted : 2012.08.12
  • Published : 2012.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Burning mouth syndrome(BMS) is defined as chronic, painful burning sensation in the oral mucosa. Treatments for BMS include medication and psychiatric interventions. Capsaicin, alpha-lipoic acid, and topical and systemic clonazepam showed more effective in reducing the symptoms of BMS in the previous studies. The purpose of this study is to evaluate of the therapeutic efficacy of systemic clonazepam in BMS and to elucidate the relationships between such a efficacy and various clinical features, including age, pain intensity, pain duration, previous dental history and condition of oral mucosa. A retrospective clinical records audit was performed of patients diagnosed with BMS between January 2011 and August 2012. Patients were prescribed 0.5 mg clonazepam two times daily. Pain was assessed by patients on an 11-point numeric rating scale (NRS; 0 to 10) before and 1-2 weeks after systemic administration of clonazepam. The efficacy of clonazepam was evaluated in terms of patient's age, initial pain intensity, pain duration, presence or absence of precipitating event, condition of the tongue, presence or absence of denture. A total of 50 patients (46 women, 4 men) were included in this study. The patients were divided into two or three groups according to above clinical features. The amount of mean NRS reduction in patients with severe initial pain was $3.33{\pm}2.74$, whereas that in patients with mild initial pain was $1.64{\pm}1.54$. The amount of mean NRS reduction in oldest patients was $3.53{\pm}1.94$ (${\geq}$70yrs), and those in another younger patients were $2.88{\pm}1.80$(< 60yrs) and $1.54{\pm}2.86$(60yrs ${\leq}$ age < 70yrs), respectively. It was concluded that the older patients and the patients with higher intensity of initial pain tend to show better efficacy of clonazepam. However, There were no statistically significant differences according to pain duration, presence or absence of precipitating events, tongue fissuring, and wearing dentures.

구강작열감증후군은 구강점막의 만성통증성 작열감이다. 구강작열감증후군의 치료로는 약물치료, 심리치료가 있다. 과거의 연구를 통해 캡사이신, 알파-리포산, 도포용 클로나제팜, 전신적 클로나제팜이 구강작열감증후군 증상의 감소에 효과적임이 보고되었다. 이 연구의 목적은 구강작열감증후군 환자에게 전신적 클로나제팜을 투여하여 치료 효과를 평가하고 약제의 효능과 연령, 통증의 강도, 통증의 기간, 과거의 치과병력, 구강점막 상태 등의 다양한 임상적 특징과의 관계를 밝히는 것이다. 이 연구는 2011년 1월과 2012년 8월 사이에 구강작열감증후군으로 진단된 환자를 대상으로 후향적 임상자료 분석을 통해 이루어졌다. 환자들에게 0.5mg 클로나제팜을 하루 2회 처방하였다. 통증은 전신적 클로나제팜의 투여 전과 투여 1-2주 후에 11-점 숫자등급척도(11-point numeric rating scale, NRS)를 통해 측정되었다. 클로나제팜의 효능은 환자의 연령, 초기 통증 강도, 통증 지속기간, 유발인자의 존재유무, 혀의 상태, 의치착용 유무에 따라 평가되었다. 총 50명의 환자(여성 46명, 남성 4명)가 연구에 참여하였다. 환자들은 상기의 임상적 특징에 따라 2-3개의 군으로 나누었다. 강한 초기 통증 환자들의 평균 NRS 감소량은 $3.33{\pm}2.74$인 반면에 경도 혹은 중등도 초기 통증 환자들의 평균 NRS 감소량은 $1.64{\pm}1.54$였다. 70세 이상의 가장 높은 연령의 환자군의 평균 NRS 감소량은 $3.53{\pm}1.94$였으며, 60세 이하 환자군에서는 $2.88{\pm}1.80$, 60세에서 70세 사이 환자군에서는 $1.54{\pm}2.86$의 감소량을 보였다. 결론적으로 높은 연령의 환자들과 강한 초기 통증을 가진 환자들에게서 클로나제팜의 효능이 뛰어난 경향이 있다. 그러나 통증 기간, 유발인자 유무, 열구설 유무, 의치 장착 유무에 의한 클로나제팜의 효능의 차이는 통계학적 유의성이 없었다.

Keywords

References

  1. Ship JA, Grushka M, Lipton JA, Mott AE, Sessle BJ, Dionne RA. Burning mouth syndrome: and update. J Am Dent Assoc 1995;126:842-53. https://doi.org/10.14219/jada.archive.1995.0305
  2. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician. 2002 Feb 15;65(4): 615-20.
  3. Zakrzewska JM, Forssel H, Glenny AM. Interventions for the treatment of burning mouth syndrome. The Cochrane Database of Systematic reviews, Issue 1, 2005.
  4. Torgerson RR. Burning mouth syndrome. Dermatol Ther. 2010 May-Jun;23(3):291-8. https://doi.org/10.1111/j.1529-8019.2010.01325.x
  5. de Moraes M, do Amaral Bezerra BA, da Rocha Neto PC, de Oliveira Soares AC, Pinto LP, de Lisboa Lopes Costa A. Randomized trials for the treatment of burning mouth syndrome: an evidence-based review of the literature. J Oral Pathol Med.2012 Apr;41 (4):281-7. https://doi.org/10.1111/j.1600-0714.2011.01100.x
  6. Heckmann SM, Kirchner E, Grushka M, Wichmann MG, Hummel T. A double-blind study on clonazepam in patients with burning mouth syndrome. Laryngoscope. 2012 Apr;122(4):813-6. https://doi.org/10.1002/lary.22490
  7. Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, Sapelli P. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain. 2005 Jun;115(3):332-7. https://doi.org/10.1016/j.pain.2005.03.028
  8. Yilmaz Z, Renton T, Yiangou Y, Zakrzewska J, Chessell IP, Bountra C, Anand P. Burning mouth syndrome as a trigeminal small fibre neuropathy: Increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci. 2007 Sep;14(9):864-71. https://doi.org/10.1016/j.jocn.2006.09.002
  9. Hagelberg N, Jääskeläinen SK, Martikainen IK, Mansikka H, Forssell H, Scheinin H, Hietala J, Pertovaara A. Striatal dopamine D2 receptors in modulation of pain in humans: a review. Eur J Pharmacol. 2004 Oct 1;500(1-3):187-92. https://doi.org/10.1016/j.ejphar.2004.07.024
  10. Hagelberg N, Forssell H, Rinne JO, Scheinin H, Taiminen T, Aalto S, Luutonen S, Nagren K, Jaaskelainen S. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain. 2003 Jan;101(1-2):149-54. https://doi.org/10.1016/S0304-3959(02)00323-8
  11. Drugan RC, Holmes PV. Central and peripheral benzodiazepine receptors: involvement in an organism's response to physical and psychological stress. Neurosci Biobehav Rev. 1991 Summer;15(2): 277-98. https://doi.org/10.1016/S0149-7634(05)80007-7
  12. Mihic SJ, Whiting PJ, Klein RL, Wafford KA, Harris RA. A single amino acid of the human gammaaminobutyric acid type A receptor gamma 2 subunit determines benzodiazepine efficacy. J Biol Chem 1994;269:32768-73.
  13. EM Sellers, JM Khanna. Anxiolytics, hypnotics, and sedatives. H Kalant, W Roschlau (Eds.), Principles of medical pharmacology., Toronto, 1989, BC Decker Publisher., pp. 255-264
  14. WM Burnham. Antiseizure drugs (anticonvulsants). H Kalant, W Roschlau (Eds.), Principles of medical pharmacology., Toronto, 1989, BC Decker Publisher., pp. 203-213.
  15. Gremeau-Richard C, Woda A, Navez ML, Attal N, Bouhassira D, Gagnieu MC, Laluque JF, Picard P, Pionchon P, Tubert S. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain. 2004 Mar;108(1-2):51-7. https://doi.org/10.1016/j.pain.2003.12.002
  16. Grushka M, Epstein J, Mott A. An open-label, dose escalation pilot study of the effect of clonazepam in burning mouth syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998 Nov;86(5):557-61. https://doi.org/10.1016/S1079-2104(98)90345-6
  17. Tenn CC, Niles LP. Mechanisms underlying the antidopaminergic effect of clonazepam and melatonin in striatum. Neuropharmacology. 1997 Nov-Dec;36(11 -12):1659-63. https://doi.org/10.1016/S0028-3908(97)00165-2
  18. Woda A, Pionchon P. A unified concept of idiopathic orofacial pain: pathophysiologic features. J Orofac Pain. 2000 Summer;14(3):196-212.
  19. Dalezios Y, Matsokis N. Brain benzodiazepine binding in aged rats. Neurochem Int. 1998 Feb;32(2):213-7. https://doi.org/10.1016/S0197-0186(97)00089-2
  20. Riss J, Cloyd J, Gates J, Collins S. Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. https://doi.org/10.1111/j.1600-0404.2008.01004.x
  21. American Dental Association status report on the occurrence of galvanic corrosion in the mouth and its potential effects. Council on Dental Materials, instruments, and Equipment. J Am Dent Assoc 1987;15:783-7.
  22. Bork K, Hoede N, Korting GW, Burgdorf W, Young S. Diseases of the oral mucosa and the lips. 2nd ed. Philadelphia: W. B Saunders; 1993 . p. 20-3.
  23. Avcu N, Kanli A. The prevalence of tongue lesions in 5150 Turkish dental outpatients. Oral Dis. 2003 Jul;9(4):188-95. https://doi.org/10.1034/j.1601-0825.2003.02933.x
  24. Kullaa-Mikkonen A. Familial study of fissured tongue. Scand J Dent Res. 1988 Aug;96(4):366-75.
  25. Ching V, Grushka M, Darling M, Su N. Increased prevalence of geographic tongue in burning mouth complaints: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Aug 15.
  26. Siverman S, Eversole L, Truelove E. Essential of Oral medicine. BC Decker Inc.; 2001 . p . 335.
  27. van Joost T, van Ulsen J, van Loon LA. Contact allergy to denture materials in the burning mouth syndrome. Contact Dermatitis. 1988 Feb;18(2):97-9. https://doi.org/10.1111/j.1600-0536.1988.tb02748.x

Cited by

  1. Retrospective Review of Effectiveness of Various Pharmacological Agents in Treating Burning Mouth Syndrome vol.41, pp.1, 2016, https://doi.org/10.14476/jomp.2016.41.1.21
  2. 수면장애가 구강작열감 증후군에 미치는 영향에 대한 고찰 vol.38, pp.4, 2012, https://doi.org/10.14476/jomp.2013.38.4.313